Adrian Rawcliffe
CIK 1555851 · Chief Executive Officer · last filed 2025-12-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.17M
Companies
3
Total Filings
53
Lifetime Open-Market Net
-$2.30M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WVE | Director | 54,700 | $5.89 | $322.2K | -$739.4K | 12 | 2025-12-10 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Chief Executive Officer | 44,327 | $0.06 | $2.6K | -$518.7K | 30 | 2025-02-20 |
| ASND | CEO and CFO | 3,318 | $254.44 | $844.2K | -$1.04M | 7 | 2019-09-03 |
Recent Filings · Page 2 of 6
53 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-14 | WVE | Grant (A) | +16,115 | $0 | EDGAR |
| 2024-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −39,384 | -$27.6K | EDGAR |
| 2024-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-12 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −29,202 | -$24.7K | EDGAR |
| 2023-09-01 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −2,403 | -$1.9K | EDGAR |
| 2023-08-09 | WVE | Grant (A) | — | $0 | EDGAR |
| 2023-06-27 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −2,333 | -$2.1K | EDGAR |
| 2023-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −10,057 | -$18.7K | EDGAR |
| 2023-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-12 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −31,805 | -$54.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.